NEJM January 22,2026 Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
NEJM January 22,2026 Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
-
Narrated by:
-
Written by:
About this listen
This clinical study investigates a promising new treatment combination for patients facing advanced triple-negative breast cancer, a particularly aggressive form of the disease. Researchers compared the effectiveness of pairing the drug sacituzumab govitecan with pembrolizumab against the standard approach of using traditional chemotherapy with immunotherapy. The trial found that patients receiving the new combination therapy experienced a significantly longer duration of progression-free survival, maintaining stability for over eleven months on average. Beyond just slowing the disease, this experimental regimen demonstrated a higher objective response rate and proved easier for patients to tolerate, resulting in far fewer people stopping treatment due to side effects. Ultimately, the study suggests this dual-drug approach offers a superior therapeutic alternativefor previously untreated patients with this specific cancer subtype.